Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models

P. Oliva, A. Decio, V. Castiglioni, A. Bassi, E. Pesenti, M. Cesca, E. Scanziani, D. Belotti, R. Giavazzi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Bevacizumab is being incorporated as first-line therapy with standard-of-care chemotherapy on epithelial ovarian carcinoma (EOC). We investigated bevacizumab combined with chemotherapy on tumour progression and mouse survival in EOC xenograft models. Methods: Bevacizumab was administered concomitantly with cisplatin plus paclitaxel (DDP+PTX), continued after induction (maintenance) or started after chemotherapy. The effect on tumour progression was monitored by bioluminescence imaging (BLI) (1A9-luc xenograft). Tumour dissemination into the peritoneal organs and ascites formation (HOC22 xenograft) was evaluated by histological analysis at the end of treatment (interim) and at euthanasia (survival). The effects on overall survival (OS) were investigated in both EOC models. Results: Bevacizumab with PTX+DDP delayed tumour progression in mice bearing EOC xenografts. OS was significantly extended, with complete responses, by bevacizumab continued after stopping chemotherapy in the HOC22 xenograft. Bevacizumab alone inhibited ascites formation, with only limited effect on tumour burden, but combined with PTX+DDP reduced ascites and metastases. Bevacizumab started after induction with PTX+DDP and maintained was equally effective on tumour progression and survival on 1A9-luc xenograft. Conclusion: Bevacizumab combined with chemotherapy not only affected tumour progression, but when administered as maintenance regimen significantly prolonged survival, reducing ascites, and tumour dissemination. We believe our findings are consistent with the clinical results and shed light on the potential effects of this kind of treatment on tumour progression.

Original languageEnglish
Pages (from-to)360-369
Number of pages10
JournalBritish Journal of Cancer
Volume107
Issue number2
DOIs
Publication statusPublished - Jul 10 2012

Fingerprint

Heterografts
Maintenance
Carcinoma
Ascites
Neoplasms
Drug Therapy
Euthanasia
TP protocol
Bevacizumab
Standard of Care
Tumor Burden
Therapeutics
Neoplasm Metastasis

Keywords

  • bevacizumab
  • cisplatin
  • metastasis
  • ovarian carcinoma
  • paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. / Oliva, P.; Decio, A.; Castiglioni, V.; Bassi, A.; Pesenti, E.; Cesca, M.; Scanziani, E.; Belotti, D.; Giavazzi, R.

In: British Journal of Cancer, Vol. 107, No. 2, 10.07.2012, p. 360-369.

Research output: Contribution to journalArticle

Oliva, P. ; Decio, A. ; Castiglioni, V. ; Bassi, A. ; Pesenti, E. ; Cesca, M. ; Scanziani, E. ; Belotti, D. ; Giavazzi, R. / Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. In: British Journal of Cancer. 2012 ; Vol. 107, No. 2. pp. 360-369.
@article{bba93cfb5c8c457c81ff5fd376e14941,
title = "Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models",
abstract = "Background: Bevacizumab is being incorporated as first-line therapy with standard-of-care chemotherapy on epithelial ovarian carcinoma (EOC). We investigated bevacizumab combined with chemotherapy on tumour progression and mouse survival in EOC xenograft models. Methods: Bevacizumab was administered concomitantly with cisplatin plus paclitaxel (DDP+PTX), continued after induction (maintenance) or started after chemotherapy. The effect on tumour progression was monitored by bioluminescence imaging (BLI) (1A9-luc xenograft). Tumour dissemination into the peritoneal organs and ascites formation (HOC22 xenograft) was evaluated by histological analysis at the end of treatment (interim) and at euthanasia (survival). The effects on overall survival (OS) were investigated in both EOC models. Results: Bevacizumab with PTX+DDP delayed tumour progression in mice bearing EOC xenografts. OS was significantly extended, with complete responses, by bevacizumab continued after stopping chemotherapy in the HOC22 xenograft. Bevacizumab alone inhibited ascites formation, with only limited effect on tumour burden, but combined with PTX+DDP reduced ascites and metastases. Bevacizumab started after induction with PTX+DDP and maintained was equally effective on tumour progression and survival on 1A9-luc xenograft. Conclusion: Bevacizumab combined with chemotherapy not only affected tumour progression, but when administered as maintenance regimen significantly prolonged survival, reducing ascites, and tumour dissemination. We believe our findings are consistent with the clinical results and shed light on the potential effects of this kind of treatment on tumour progression.",
keywords = "bevacizumab, cisplatin, metastasis, ovarian carcinoma, paclitaxel",
author = "P. Oliva and A. Decio and V. Castiglioni and A. Bassi and E. Pesenti and M. Cesca and E. Scanziani and D. Belotti and R. Giavazzi",
year = "2012",
month = "7",
day = "10",
doi = "10.1038/bjc.2012.261",
language = "English",
volume = "107",
pages = "360--369",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models

AU - Oliva, P.

AU - Decio, A.

AU - Castiglioni, V.

AU - Bassi, A.

AU - Pesenti, E.

AU - Cesca, M.

AU - Scanziani, E.

AU - Belotti, D.

AU - Giavazzi, R.

PY - 2012/7/10

Y1 - 2012/7/10

N2 - Background: Bevacizumab is being incorporated as first-line therapy with standard-of-care chemotherapy on epithelial ovarian carcinoma (EOC). We investigated bevacizumab combined with chemotherapy on tumour progression and mouse survival in EOC xenograft models. Methods: Bevacizumab was administered concomitantly with cisplatin plus paclitaxel (DDP+PTX), continued after induction (maintenance) or started after chemotherapy. The effect on tumour progression was monitored by bioluminescence imaging (BLI) (1A9-luc xenograft). Tumour dissemination into the peritoneal organs and ascites formation (HOC22 xenograft) was evaluated by histological analysis at the end of treatment (interim) and at euthanasia (survival). The effects on overall survival (OS) were investigated in both EOC models. Results: Bevacizumab with PTX+DDP delayed tumour progression in mice bearing EOC xenografts. OS was significantly extended, with complete responses, by bevacizumab continued after stopping chemotherapy in the HOC22 xenograft. Bevacizumab alone inhibited ascites formation, with only limited effect on tumour burden, but combined with PTX+DDP reduced ascites and metastases. Bevacizumab started after induction with PTX+DDP and maintained was equally effective on tumour progression and survival on 1A9-luc xenograft. Conclusion: Bevacizumab combined with chemotherapy not only affected tumour progression, but when administered as maintenance regimen significantly prolonged survival, reducing ascites, and tumour dissemination. We believe our findings are consistent with the clinical results and shed light on the potential effects of this kind of treatment on tumour progression.

AB - Background: Bevacizumab is being incorporated as first-line therapy with standard-of-care chemotherapy on epithelial ovarian carcinoma (EOC). We investigated bevacizumab combined with chemotherapy on tumour progression and mouse survival in EOC xenograft models. Methods: Bevacizumab was administered concomitantly with cisplatin plus paclitaxel (DDP+PTX), continued after induction (maintenance) or started after chemotherapy. The effect on tumour progression was monitored by bioluminescence imaging (BLI) (1A9-luc xenograft). Tumour dissemination into the peritoneal organs and ascites formation (HOC22 xenograft) was evaluated by histological analysis at the end of treatment (interim) and at euthanasia (survival). The effects on overall survival (OS) were investigated in both EOC models. Results: Bevacizumab with PTX+DDP delayed tumour progression in mice bearing EOC xenografts. OS was significantly extended, with complete responses, by bevacizumab continued after stopping chemotherapy in the HOC22 xenograft. Bevacizumab alone inhibited ascites formation, with only limited effect on tumour burden, but combined with PTX+DDP reduced ascites and metastases. Bevacizumab started after induction with PTX+DDP and maintained was equally effective on tumour progression and survival on 1A9-luc xenograft. Conclusion: Bevacizumab combined with chemotherapy not only affected tumour progression, but when administered as maintenance regimen significantly prolonged survival, reducing ascites, and tumour dissemination. We believe our findings are consistent with the clinical results and shed light on the potential effects of this kind of treatment on tumour progression.

KW - bevacizumab

KW - cisplatin

KW - metastasis

KW - ovarian carcinoma

KW - paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=84863722405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863722405&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.261

DO - 10.1038/bjc.2012.261

M3 - Article

VL - 107

SP - 360

EP - 369

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -